ClinicalTrials.gg
CompletedNCT05343364Updated Apr 23, 2025Results posted

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease

A Phase 1 interventional study of Vonoprazan in Gastroesophageal Reflux, sponsored by Phathom Pharmaceuticals, Inc.. Completed at 10 sites in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-04-23.

Sponsored by Phathom Pharmaceuticals, Inc. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing vonoprazan in Gastroesophageal Reflux — 5 open to participants now, 5 under way, 1 of them phase 3. vonoprazan · Gastroesophageal Reflux.

Enrollment
14th of 16
24 · median 118
Started
2022
with 1 other
Phase 1
5 of 16
none open now
Registered
7th of 16
by date
Lead sponsor
4 of 16
Phathom Pharmaceuticals, Inc.

Among the 16 studies testing vonoprazan in Gastroesophageal Reflux, this one is the 14th largest by enrollment, is one of 2 that started in 2022, is one of 5 in phase 1, and was the 7th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

5 of the 16 studies testing vonoprazan in Gastroesophageal Reflux are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vonoprazan

vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing vonoprazan in Gastroesophageal Reflux, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the pharmacokinetic profile of vonoprazan in adolescent participants with symptomatic gastroesophageal reflux disease (GERD).

Read the detailed description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

03

Conditions studied

  • Gastroesophageal Reflux

Keywords

  • Vonoprazan
  • Gastroesophageal Reflux
  • GERD
  • Adolescents
  • Pharmacokinetics
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant is 12 to 17 years of age, inclusive, at the time of signing and throughout study participation.
  • The participant has a body weight within the 5th through 95th percentile by age, inclusive, as determined by the National Center for Health Statistics.
  • The participant has a medical history of symptoms of GERD for at least 3 months prior to screening, based on physical examination, current symptoms (eg, heartburn), or diagnostic tests (eg, pH or endoscopy). Notes in the medical records and/or other source documents such as prior endoscopies can be used to support the diagnosis.
  • The participant has symptoms of at least moderate heartburn severity based on the GERD Symptom Assessment-Investigator scale performed at screening.
  • The participant must be able to swallow study drug.
  • Parent or legal guardian (ie, legally authorized representative [LAR]) is willing and able to complete the informed consent process and comply with study procedures and visit schedule. The participant will provide assent as applicable.
  • A female participant of who is or may be sexually active with a nonsterilized male partner agrees to routinely use adequate from the signing of informed consent until 2 weeks after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • The participant has used prescription or non-prescription proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs) within 7 days prior to randomization or requires their use during the Treatment Period.
  • The participant has used sucralfate or antacids within 1 day prior to randomization or requires their use during the Treatment Period.
  • The participant has received other agents affecting digestive organs, including muscarinic antagonists (eg, hyoscyamine), prokinetics, oral anticholinergic agents, prostaglandins, bismuth from 30 days prior to Day 1 or requires their use during the course of the study.
  • The participant has received atazanavir sulfate or rilpivirine hydrochloride from 5 days prior to Day 1 or requires their use during the course of the study.
  • The participant has received any compound (including vonoprazan) within 30 days prior to the start of the Screening Period.
  • The participant is an immediate family member or is in a dependent relationship with a study site employee who is involved in the conduct of this study (eg, child, sibling) or who may have consented under duress.
  • The participant requires hospitalization or has surgery scheduled during the course of the study or has undergone major surgical procedures within 30 days prior to the Screening Period.
  • The participant has undergone prior gastrointestinal surgeries such as fundoplication.
  • The participant has any abnormal laboratory test values at the start of the Screening Period.
  • The participant has a history of or allergies to vonoprazan (including the formulation : D-mannitol, microcrystalline cellulose, hydroxypropyl cellulose, fumaric acid, croscarmellose sodium, magnesium stearate, hypromellose, macrogol 8000, and titanium oxide, or red or yellow ferric oxide).
  • The participant used any prescription (excluding hormonal ) or over-the-counter medications (including inducers), including herbal or nutritional supplements, within 14 days (or 5 half-lives) before the first dose of study drug or throughout the study. NOTE: Acid suppressive therapies are considered separately under exclusion criteria 1 and 2.
  • The participant has consumed grapefruit or grapefruit juice, Seville orange or Seville orange-containing products (eg, marmalade), or other food products that may be CYP3A4 inhibitors (eg, vegetables from the mustard green family [kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard] and charbroiled meats) within 7 days (or 5 half-lives) before the first dose of study drug or throughout the study.
  • Female participant has a positive pregnancy test at screening or check in or is lactating.
  • The participant has a positive urine drug or alcohol result at screening.
  • The participant has positive results at screening for , surface antigen, or virus.
  • In the opinion of the investigator, the participant is not suitable for entry into the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Vonoprazan 10 mg

    Participants will receive vonoprazan 10 mg once daily for 14 days.

    Drug: Vonoprazan

  • Experimental
    Vonoprazan 20 mg

    Participants will receive vonoprazan 20 mg once daily for 14 days.

    Drug: Vonoprazan

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Drug Concentration at Steady State (Cmax-ss) of Vonoprazan

    Plasma pharmacokinetic (PK) parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time.

    Time frame: Blood samples were collected predose, once between 0.5 and 2 hours, and once between 2.5 and 4 hours post-dose on Days 7 and 14

  2. Area Under the Plasma Concentration-time Curve During the Dosing Interval τ (AUCτ) of Vonoprazan

    PK parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time.

    Time frame: Blood samples were collected predose, once between 0.5 and 2 hours, and once between 2.5 and 4 hours post-dose on Days 7 and 14

  3. Apparent Oral Clearance (CL/F) of Vonoprazan

    PK parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time.

    Time frame: Blood samples were collected predose, once between 0.5 and 2 hours, and once between 2.5 and 4 hours post-dose on Days 7 and 14

  4. Apparent Central Volume of Distribution (Vc/F) of Vonoprazan

    PK parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time.

    Time frame: Blood samples were collected predose, once between 0.5 and 2 hours, and once between 2.5 and 4 hours post-dose on Days 7 and 14

Secondary outcomes

  1. Number of Participants Experiencing Adverse Events (AEs)

    AE: any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug. Treatment-emergent adverse event (TEAE): any AE that occurred after the first dose of study drug or at baseline that worsens in either intensity or frequency after the first dose of study drug. Serious AE: any AE for which the following occurred: death, was life threatening, hopsitalization or prolongation of hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or the AE was deemed an important medical event. Related AE: any AE that follows a reasonable temporal sequence from administration of study drug, or for which possible involvement of the drug cannot be ruled out, although factors other than the study drug may also be responsible. Clinically significant changes from baseline in laboratory test values, (hematology, serum chemistry and urinalysis), electrocardiograms and vital signs were reported as AEs.

    Time frame: Up to Day 28

07

Results

Posted Jun 3, 2024

Participant flow

A total of 24 participants were enrolled into this study in the United States between May 2022 and June 2023.

Participant flow — Overall Study
MilestoneVonoprazan 10 mg QDVonoprazan 20 mg QD
Started1212
Completed1211
Not completed01
Withdrew: Miscellaneous01

Outcome measures

PrimaryMaximum Observed Drug Concentration at Steady State (Cmax-ss) of Vonoprazan

Plasma pharmacokinetic (PK) parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time.

Time frame:
Blood samples were collected predose, once between 0.5 and 2 hours, and once between 2.5 and 4 hours post-dose on Days 7 and 14
Reported as:
Mean · ng/mL
Maximum Observed Drug Concentration at Steady State (Cmax-ss) of Vonoprazan
ng/mLVonoprazan 10 mg QDVonoprazan 20 mg QD
Maximum Observed Drug Concentration at Steady State (Cmax-ss) of Vonoprazan13.4 (6.57 to 25.6)26.7 (13.1 to 49.1)
PrimaryArea Under the Plasma Concentration-time Curve During the Dosing Interval τ (AUCτ) of Vonoprazan

PK parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time.

Time frame:
Blood samples were collected predose, once between 0.5 and 2 hours, and once between 2.5 and 4 hours post-dose on Days 7 and 14
Reported as:
Mean · h*ng/mL
Area Under the Plasma Concentration-time Curve During the Dosing Interval τ (AUCτ) of Vonoprazan
h*ng/mLVonoprazan 10 mg QDVonoprazan 20 mg QD
Area Under the Plasma Concentration-time Curve During the Dosing Interval τ (AUCτ) of Vonoprazan94.6 (56.0 to 165)208 (95.6 to 381)
PrimaryApparent Oral Clearance (CL/F) of Vonoprazan

PK parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time.

Time frame:
Blood samples were collected predose, once between 0.5 and 2 hours, and once between 2.5 and 4 hours post-dose on Days 7 and 14
Reported as:
Mean · L/h
Apparent Oral Clearance (CL/F) of Vonoprazan
L/hVonoprazan 10 mg QDVonoprazan 20 mg QD
Apparent Oral Clearance (CL/F) of Vonoprazan124 (60.5 to 179)117 (52.5 to 209)
PrimaryApparent Central Volume of Distribution (Vc/F) of Vonoprazan

PK parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time.

Time frame:
Blood samples were collected predose, once between 0.5 and 2 hours, and once between 2.5 and 4 hours post-dose on Days 7 and 14
Reported as:
Mean · liters
Apparent Central Volume of Distribution (Vc/F) of Vonoprazan
litersVonoprazan 10 mg QDVonoprazan 20 mg QD
Apparent Central Volume of Distribution (Vc/F) of Vonoprazan686 (314 to 1280)704 (311 to 1110)
SecondaryNumber of Participants Experiencing Adverse Events (AEs)

AE: any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug. Treatment-emergent adverse event (TEAE): any AE that occurred after the first dose of study drug or at baseline that worsens in either intensity or frequency after the first dose of study drug. Serious AE: any AE for which the following occurred: death, was life threatening, hopsitalization or prolongation of hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or the AE was deemed an important medical event. Related AE: any AE that follows a reasonable temporal sequence from administration of study drug, or for which possible involvement of the drug cannot be ruled out, although factors other than the study drug may also be responsible. Clinically significant changes from baseline in laboratory test values, (hematology, serum chemistry and urinalysis), electrocardiograms and vital signs were reported as AEs.

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs)
ParticipantsVonoprazan 10 mg QDVonoprazan 20 mg QD
Any TEAEs41
Any Serious TEAEs00
Any Study Drug-related TEAEs00
Any Serious Study Drug-related TEAEs00
Any TEAE Leading to Treatment Discontinuation00
Any TEAE Leading to Study Discontinuation00
Any AEs Leading to Death00

Adverse events

Collected over Up to Day 28. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vonoprazan 10 mg QD0/12 (0%)0/12 (0%)4/12 (33.3%)
Vonoprazan 20 mg QD0/12 (0%)0/12 (0%)1/12 (8.3%)
Most frequent other events
Most frequent other events
EventVonoprazan 10 mg QDVonoprazan 20 mg QD
CellulitisInfections and infestations1/120/12
Enterocolitis infectiousInfections and infestations0/121/12
Gastrooesophageal reflux diseaseGastrointestinal disorders1/120/12
Back painMusculoskeletal and connective tissue disorders1/120/12
MigraineNervous system disorders1/120/12
AnxietyPsychiatric disorders1/120/12

Baseline characteristics

Safety Set: inclusive of all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Vonoprazan 10 mg QDVonoprazan 20 mg QDTotal
Mean14.3 ± 1.7815.2 ± 1.7514.8 ± 1.78
Sex: Female, Male
Sex: Female, Male(Participants)Vonoprazan 10 mg QDVonoprazan 20 mg QDTotal
Female6713
Male6511
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Vonoprazan 10 mg QDVonoprazan 20 mg QDTotal
Hispanic or Latino426
Not Hispanic or Latino61016
Unknown or Not Reported202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Vonoprazan 10 mg QDVonoprazan 20 mg QDTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American358
White9716
More than one race000
Unknown or Not Reported000
08

Study locations

10 sites
  • University of South Alabama (USA) Physicians Group
    Mobile, Alabama 36604-1541, United States
  • Preferred Research Partners, Inc.
    Little Rock, Arkansas 72211, United States
  • Advanced Research Center - Elligo
    Anaheim, California 92805, United States
  • Infinite Clinical Trials
    Morrow, Georgia 30260-2342, United States
  • Legacy Clinical Solutions: Tandem Clinical Research, LLC
    Marrero, Louisiana 70072-3151, United States
  • Boston Specialists
    Boston, Massachusetts 02111, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • PriMED Clinical Research
    Dayton, Ohio 45429, United States
  • ARC Clinical Research at Four Points
    Austin, Texas 78726, United States
  • Pediatric Gastro
    El Paso, Texas 79902, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in May 2023, 12 months.

Results were first posted in Jun 2024, 1 year after primary completion.

Of 28 industry-sponsored phase 1 interventional studies under Gastroesophageal Reflux, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's 12 months is above that.

Counting every sponsor, half of 34 studies reached it within 4 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2022
First posted
Apr 25, 2022
StartActual
May 9, 2022
Primary completionActual
May 30, 2023
CompletionActual
Jun 13, 2023
Results first posted
Jun 3, 2024
Last update
Apr 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05343364
Lead sponsor
Phathom Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Apr 25, 2022
Start date
May 9, 2022
Primary completion
May 30, 2023
Completion
Jun 13, 2023
Results posted
Jun 3, 2024
Last update
Apr 23, 2025

Study contacts

Medical Director
study director · Phathom Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion